XML 14 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 5 Months Ended | 7 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jun. 14, 2024 | Dec. 31, 2024 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Pay vs Performance [Table Text Block] |  |  |  |
Year |  | Summary Compensation Table Total for the Principal Executive Officer (“PEO”) (Current) (1) ($) |  |  | CAP to PEO (Current) (2)(3) ($) |  |  | Summary Compensation Table Total for PEO (Former) (1) ($) |  |  | CAP to PEO (Former) (2)(3) ($) |  |  | Average Summary Compensation Table Total for Non-PEO NEOs (4) ($) |  |  | Average CAP to Non-PEO NEOs (3)(4) ($) (4) |  |  | Value of Initial Fixed $100 Investment based on Total Stockholder Return (“TSR”) (5) ($) |  |  | Net (Loss) Income (6) ($) |
2024 |  | $ | 175,833 |  |  | $ | 175,833 |  |  | $ | 420,231 |  |  | $ | (1,100,241 | ) |  | $ | 120,066 |  |  | $ | 94,166 |  |  |  | 29 |  |  | $ | (27,161,219 | )
2023 |  |  | 2,884,326 |  |  |  | (6,400,989 | ) |  |  | - |  |  |  | - |  |  |  | 444,756 |  |  |  | (2,041,030 | ) |  |  | 195 |  |  |  | (8,218,163 | )
2022 |  |  | 261,827 |  |  |  | (4,105,250 | ) |  |  | - |  |  |  | - |  |  |  | 234,657 |  |  |  | - |  |  |  | 29 |  |  |  | (15,197,336 | )
Named Executive Officers, Footnote [Text Block] |  |  |  |
(1) | The dollar amounts reported in this column are the amounts of total compensation reported in the “Total” column of the Summary Compensation Table for the 2022, 2023 and 2024 fiscal years for the persons who served as our PEO for the applicable year. Effective April 16, 2021, Dr. Christopher Chapman was appointed as President and Chief Medical Officer, and since such date and until June 14, 2024, has performed the duties of PEO. Effective June 13, 2024, Dr. Glass was appointed as President and Chief Medical Officer. Dr. Glass’ compensation information for 2023 and 2022 is not included because he did not serve as our PEO during 2022 or 2023. For additional information, see “Executive Compensation—Summary Compensation Table.”
(2) | The dollar amounts reported in this column represent the amount of “CAP” to our PEO, as computed in accordance with Item 402(v) of Regulation S-K.
(3) | The following table reflects the adjustments made to compute CAP for each applicable year:
(4) | The dollar amounts reported in this column represent the average of the amounts reported for our Non-PEO NEOs as a group in the “Total” column of the Summary Compensation Table in each applicable year. The Non-PEO NEOs in each applicable year were Ian Rhodes and Dr. Adam Kaplin, as applicable. Effective November 14, 2024, Dr. Adam Kaplin resigned as a Non-PEO NEO. Dr. Kaplin’s compensation information for 2022 and 2023 is included in this table as a former Non-PEO NEO in accordance with Item 402(v) of Regulation S-K.
(5) | The amounts reported in this column reflect our cumulative TSR, assuming an initial fixed $100 investment in the Company for the period starting January 1, 2022 through the end of each listed fiscal year. Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. No dividends were paid on stock or option awards in 2022, 2023 or 2024.
(6) | The dollar amounts reported in this column represent the amount of net loss attributable to the Company’s stockholders as reflected in our consolidated audited financial statements for each applicable year.
Adjustment To PEO Compensation, Footnote [Text Block] |  |  |  | Calculation of Compensation Actually Paid For the Years Ending December 31 2024, 2023, and 2022
|  | PEO |  |  | Former PEO |  |  | Non-PEO NEOs |  |  | PEO |  |  | Non-PEO NEOs |  |  | PEO |  |  | Non-PEO NEOs |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | PEO |  |  | Former PEO |  |  | Non-PEO NEOs |  |  | PEO |  |  | Non-PEO NEOs |  |  | PEO |  |  | Non-PEO NEOs |
|  | ($) |  |  | ($) |  |  | ($) |  |  | ($) |  |  | ($) |  |  | ($) |  |  | ($) |
Summary Compensation Table Total |  |  | 175,833 |  |  |  | 420,231 |  |  |  | 240,131 |  |  |  | 2,884,326 |  |  |  | 1,334,268 |  |  |  | 261,627 |  |  |  | 541,972 |
Adjustments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Awards |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (2,218,565 | ) |  |  | (470,490 | ) |  |  | - |  |  |  | - |
Fair Value of Equity Awards |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year. |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 440,305 |  |  |  | 51,800 |  |  |  | - |  |  |  | - |
Change in Fair Value of Outstanding and Unvested Equitry Awards Granted in the Prior Year. |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (7,047,900 | ) |  |  | (6,264,878 | ) |  |  | (4,367,077 | ) |  |  | (5,064,861 | )
Fair Value on Vesting Date of Equity Awards Granted and Vested in the Coverred Year |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 553,500 |  |  |  | 166,000 |  |  |  | - |  |  |  | - |
Change in Fair Value of Prior Year Equity Awards Vested in the Covered Year |  |  | - |  |  |  | (1,080,167 | ) |  |  | - |  |  |  | (462,850 | ) |  |  | (140,100 | ) |  |  | - |  |  |  | - |
Year-End Fair Value in the Prior Year of Equity Awards Granted in any Prior Year that are Forfieted or Expired During the Covered Year |  |  | - |  |  |  | (440,305 | ) |  |  | (51,800 | ) |  |  | (549,805 | ) |  |  | (799,688 | ) |  |  | - |  |  |  | - |
Dollar Value of Dividends or Other Earnings Paid on Stock or Option Awards in the Covered Year Prior to the Vesting Date If Not Otherwise Reflected |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Total Adjustments for Fair Value of Equity Awards |  |  | - |  |  |  | (1,520,472 | ) |  |  | (51,800 | ) |  |  | (7,066,750 | ) |  |  | (6,986,867 | ) |  |  | (4,367,077 | ) |  |  | (5,064,861 | )
Compensation Actually Paid |  |  | 175,833 |  |  |  | (1,100,241 | ) |  |  | 188,331 |  |  |  | (6,400,989 | ) |  |  | (6,123,089 | ) |  |  | (4,105,250 | ) |  |  | (4,522,889 | )
Non-PEO NEO Average Total Compensation Amount | [1] |  |  | $ 120,066 | $ 444,756 | $ 234,657
Non-PEO NEO Average Compensation Actually Paid Amount | [1],[2] |  |  | $ 94,166 | (2,041,030) |
Compensation Actually Paid vs. Total Shareholder Return [Text Block] |  |  |  | Compensation Actually Paid and Cumulative TSR The following chart sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our cumulative TSR over the three most recently completed fiscal years. |  |
Compensation Actually Paid vs. Net Income [Text Block] |  |  |  | Compensation Actually Paid and Net Loss The following chart sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our net loss during the three most recently completed fiscal years. |  |
Total Shareholder Return Amount | [3] |  |  | $ 29 | 195 | 29
Net Income (Loss) | [4] |  |  | $ (27,161,219) | (8,218,163) | (15,197,336)
Additional 402(v) Disclosure [Text Block] |  |  |  | Analysis of the Information Presented in the Pay Versus Performance Table We generally seek to incentivize long-term performance, and therefore do not specifically align our performance measures with “compensation actually paid” (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table. |  |
PEO [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
PEO Total Compensation Amount | [5] |  |  | $ 175,833 | 2,884,326 | 261,827
Compensation Actually Paid | [2],[6] |  |  | 175,833 | (6,400,989) | (4,105,250)
PEO [Member] | Summary Compensation Table Total [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | 175,833 | 2,884,326 | 261,627
PEO [Member] | Stock Awards [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (2,218,565) |
PEO [Member] | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | 440,305 |
PEO [Member] | Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (7,047,900) | (4,367,077)
PEO [Member] | Fair Value on Vesting Date of Equity Awards Granted and Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | 553,500 |
PEO [Member] | Change in Fair Value of Prior Year Equity Awards Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (462,850) |
PEO [Member] | Year End Fair Value in Prior Year of Equity Awards Granted in Any Prior Year That Forfeited or Expired During Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (549,805) |
PEO [Member] | Dollar Value of Dividends or Other Earnings Paid on Stock or Option Awards in Covered Year Prior to Vesting Date if Not Otherwise Reflected [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  |  |
PEO [Member] | Total Adjustments for Fair Value of Equity Awards [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (7,066,750) | (4,367,077)
Former PEO [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
PEO Total Compensation Amount | [5] |  |  | 420,231 |  |
Compensation Actually Paid | [2],[6] |  |  | (1,100,241) |  |
Former PEO [Member] | Summary Compensation Table Total [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | 420,231 |  |
Former PEO [Member] | Stock Awards [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  |  |
Former PEO [Member] | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  |  |
Former PEO [Member] | Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  |  |
Former PEO [Member] | Fair Value on Vesting Date of Equity Awards Granted and Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  |  |
Former PEO [Member] | Change in Fair Value of Prior Year Equity Awards Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | (1,080,167) |  |
Former PEO [Member] | Year End Fair Value in Prior Year of Equity Awards Granted in Any Prior Year That Forfeited or Expired During Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | (440,305) |  |
Former PEO [Member] | Dollar Value of Dividends or Other Earnings Paid on Stock or Option Awards in Covered Year Prior to Vesting Date if Not Otherwise Reflected [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  |  |
Former PEO [Member] | Total Adjustments for Fair Value of Equity Awards [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | (1,520,472) |  |
Dr. Christopher Chapman [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
PEO Name |  | Dr. Christopher Chapman |  |  | Dr. Christopher Chapman | Dr. Christopher Chapman
Dr. Glass [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
PEO Name |  |  | Dr. Glass |  |  |
Non-PEO NEO [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Compensation Actually Paid |  |  |  | 188,331 | $ (6,123,089) | $ (4,522,889)
Non-PEO NEO [Member] | Summary Compensation Table Total [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | 240,131 | 1,334,268 | 541,972
Non-PEO NEO [Member] | Stock Awards [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (470,490) |
Non-PEO NEO [Member] | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | 51,800 |
Non-PEO NEO [Member] | Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (6,264,878) | (5,064,861)
Non-PEO NEO [Member] | Fair Value on Vesting Date of Equity Awards Granted and Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | 166,000 |
Non-PEO NEO [Member] | Change in Fair Value of Prior Year Equity Awards Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  | (140,100) |
Non-PEO NEO [Member] | Year End Fair Value in Prior Year of Equity Awards Granted in Any Prior Year That Forfeited or Expired During Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | (51,800) | (799,688) |
Non-PEO NEO [Member] | Dollar Value of Dividends or Other Earnings Paid on Stock or Option Awards in Covered Year Prior to Vesting Date if Not Otherwise Reflected [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  |  |  |
Non-PEO NEO [Member] | Total Adjustments for Fair Value of Equity Awards [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Total Adjustments for Fair Value of Equity Awards |  |  |  | $ (51,800) | $ (6,986,867) | $ (5,064,861)
[1] | The dollar amounts reported in this column represent the average of the amounts reported for our Non-PEO NEOs as a group in the “Total” column of the Summary Compensation Table in each applicable year. The Non-PEO NEOs in each applicable year were Ian Rhodes and Dr. Adam Kaplin, as applicable. Effective November 14, 2024, Dr. Adam Kaplin resigned as a Non-PEO NEO. Dr. Kaplin’s compensation information for 2022 and 2023 is included in this table as a former Non-PEO NEO in accordance with Item 402(v) of Regulation S-K.
[2] | The following table reflects the adjustments made to compute CAP for each applicable year:
[3] | The amounts reported in this column reflect our cumulative TSR, assuming an initial fixed $100 investment in the Company for the period starting January 1, 2022 through the end of each listed fiscal year. Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. No dividends were paid on stock or option awards in 2022, 2023 or 2024.
[4] | The dollar amounts reported in this column represent the amount of net loss attributable to the Company’s stockholders as reflected in our consolidated audited financial statements for each applicable year.
[5] | The dollar amounts reported in this column are the amounts of total compensation reported in the “Total” column of the Summary Compensation Table for the 2022, 2023 and 2024 fiscal years for the persons who served as our PEO for the applicable year. Effective April 16, 2021, Dr. Christopher Chapman was appointed as President and Chief Medical Officer, and since such date and until June 14, 2024, has performed the duties of PEO. Effective June 13, 2024, Dr. Glass was appointed as President and Chief Medical Officer. Dr. Glass’ compensation information for 2023 and 2022 is not included because he did not serve as our PEO during 2022 or 2023. For additional information, see “Executive Compensation—Summary Compensation Table.”
[6] | The dollar amounts reported in this column represent the amount of “CAP” to our PEO, as computed in accordance with Item 402(v) of Regulation S-K.

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v + Details
Name: | ecd_Additional402vDisclosureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_IndividualAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_SummaryCompensationTableTotalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_StockAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInCoveredYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_ChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_FairValueOnVestingDateOfEquityAwardsGrantedAndVestedInCoveredYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_ChangeInFairValueOfPriorYearEquityAwardsVestedInCoveredYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_YearEndFairValueInPriorYearOfEquityAwardsGrantedInAnyPriorYearThatForfeitedOrExpiredDuringCoveredYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredYearPriorToVestingDateIfNotOtherwiseReflectedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=TNFA_TotalAdjustmentsForFairValueOfEquityAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=TNFA_FormerPeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=TNFA_DrChristopherChapmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=TNFA_DrGlassMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |